Partners

Our International Network of Partners

Meeting our ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. We are extremely grateful.

map

Medical Institutions

Prostate Cancer Centre (Calgary)

Northern Alberta Urology Centre (Edmonton)

Alberta Health Services (Alberta)

Vancouver Prostate Cancer Centre (Vancouver)

The Prostate Centre at The Princess Margaret Hospital (Toronto)

CHUM Groupe de soutien du cancer de la prostate (Montreal)

London Regional Cancer Program (London, ON)

Technology Platforms

Malvern (UK)

APOGEE (UK)

Nanosight

BGI Genomics (China)

Precision Nanosystems (BC)

Universities

University of Alberta (Edmonton, AB)

University of Calgary (Calgary, AB)

Western University (London, ON)

Dalhousie University (Halifax, NS)

University of Toronto (Toronto, ON)

Vanderbilt University (Nashville, TN)

Case Western Reserve University (Cleveland, OH)

Fraunhofer ITEM-R (Regensburg, Germany)

Biorepositories

Alberta Cancer Research Biobank (Calgary, Edmonton)

Australian Prostate Cancer BioResource (Australia: Melbourne, Sydney, Brisbane and Adelaide)

OICR Tumour Bank (Ontario)

Tomorrow Project 

UHN GU BioBank

Canadian Biosample Repository

Canadian Prostate Cancer Biomarker Network

Financial Resources

Alberta Cancer Foundation (Alberta)

Movember Foundation (Australia, Canada)

Terry Fox Research Institute (Canada)

Motorcycle Ride for Dad (Canada)

Prostate Cancer Canada

Alberta Innovates Health Solutions – Collaborative Research and Innovation opportunities

Alberta Lymphedema Network (Edmonton, Alberta)

University Hospital Foundation – J & J Partnership

Support Groups

Prostate Cancer Canada Network (Canada)

Prostate Cancer Canada Network (Calgary)

Prostate Cancer Canada Network (Edmonton)

Business Partners

Nanostics

Congratulations to APCaRI recipients of JAHIP grants!

Congratulations to Drs. John Lewis, Eric Hyndman, Morley Hollenberg and Harvey Quon for being awarded each with a JAHIP grant (Johnson & Johnson Alberta Health Innovation Partnership) to better diagnose prostate cancer using different platforms and to determine mutations in patients with high-risk PCa.

This is a great opportunity to start long-lasting partnerships with J&J and the University Hospital Foundation and to develop new and better tests for PCa.

The original plan was to fund 2 applications, however, due to the high quality of the proposals, the committee decided to grant 2 more.

- Catalina Vasquez